HomeCompareEGLX vs ABBV

EGLX vs ABBV: Dividend Comparison 2026

EGLX yields 800.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EGLX wins by $2773896.36M in total portfolio value
10 years
EGLX
EGLX
● Live price
800.00%
Share price
$0.25
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2773896.46M
Annual income
$2,226,430,694,490.38
Full EGLX calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — EGLX vs ABBV

📍 EGLX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEGLXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EGLX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EGLX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EGLX
Annual income on $10K today (after 15% tax)
$68,000.00/yr
After 10yr DRIP, annual income (after tax)
$1,892,466,090,316.82/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, EGLX beats the other by $1,892,466,069,260.82/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EGLX + ABBV for your $10,000?

EGLX: 50%ABBV: 50%
100% ABBV50/50100% EGLX
Portfolio after 10yr
$1386948.28M
Annual income
$1,113,215,359,631.07/yr
Blended yield
80.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

EGLX
Analyst Ratings
1
Buy
Consensus: Buy
Price Target
$0.50
+100.0% upside vs current
Range: $0.50 — $0.50
Altman Z
-1.7
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EGLX buys
0
ABBV buys
0
No recent congressional trades found for EGLX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEGLXABBV
Forward yield800.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$2773896.46M$102.3K
Annual income after 10y$2,226,430,694,490.38$24,771.77
Total dividends collected$2730603.49M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$0.50$256.15

Year-by-year: EGLX vs ABBV ($10,000, DRIP)

YearEGLX PortfolioEGLX Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$90,700$80,000.00$11,550$430.00+$79.2KEGLX
2$775,180$678,130.84$13,472$627.96+$761.7KEGLX
3$6,246,019$5,416,576.76$15,906$926.08+$6.23MEGLX
4$47,472,138$40,788,897.61$19,071$1,382.55+$47.45MEGLX
5$340,525,323$289,730,135.14$23,302$2,095.81+$340.50MEGLX
6$2,306,680,888$1,942,318,792.24$29,150$3,237.93+$2306.65MEGLX
7$14,764,459,529$12,296,310,979.28$37,536$5,121.41+$14764.42MEGLX
8$89,354,478,583$73,556,506,887.09$50,079$8,338.38+$89354.43MEGLX
9$511,650,252,638$416,040,960,553.41$69,753$14,065.80+$511650.18MEGLX
10$2,773,896,464,813$2,226,430,694,490.38$102,337$24,771.77+$2773896.36MEGLX

EGLX vs ABBV: Complete Analysis 2026

EGLXStock

Enthusiast Gaming Holdings Inc. engages in the media, content, entertainment, and esports businesses the United States, Canada, and internationally. The company operates an online network of approximately 100 gaming related websites; owns and operates Enthusiast Gaming Live Expo, a video-gaming expo; provides management and support services to players involved in professional gaming; owns and manages esports teams for various games comprising Call of Duty, Madden NFL, Fortnite, Overwatch, Super Smash Bros., Rocket League, and Valorant; and produces and programs approximately 30 weekly shows across AVOD and OTT channels, and represents approximately 500 gaming influencers on YouTube and Twitch. It also operates Luminosity Gaming, an eSports franchise; and hosts B2B and consumer mobile gaming events. The company was incorporated in 2018 and is headquartered in Toronto, Canada.

Full EGLX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this EGLX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EGLX vs SCHDEGLX vs JEPIEGLX vs OEGLX vs KOEGLX vs MAINEGLX vs JNJEGLX vs MRKEGLX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.